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Results. From the 95 patients treated, we analyse the subgroup of 85 patients who had enough follow-up to evaluate late toxicity.
The mean age at treatment was 67 (range 45–92). Most of the tumors were located at external superior cuadrant (41.2%) or joint
of superior cuadrants (15.3%). Eighty per cent were inﬁltrating ductal carcinomas with an 84.7% of stage IA tumors and 70% of
luminal A molecular subtypes. Only 6 patients were grade 3, they were treated with HDR-BT due to their age. Fifty-one patients
received adjuvant hormonal therapy. Most patients (70.6%) were treated using 7 needles (range 4–12) in 2–3 planes, with a mean
active length of 4.5 cm (range 2–7 cm). With a mean follow-up of 23.47 months (range 6–124), only one patient has experimented
a recurrence in the ipsilateral breast 21 months after the procedure, she had a triple negative tumor and was treated with
mastectomy without disease nowadays. Three patients died from another non-related disease (cerebral-vascular stroke), none
of them died from breast cancer disease. Late toxicity was mild, with 27% and 5% of grade I cutaneous and subcutaneous toxicity
respectively.
Conclusions. Accelerated partial breast irradiation using HDR-BT is a proper approach, with excellent results in terms of disease
free survival and very good tolerance in terms of normal tissue late toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.703
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Purpose. Low dose rate (LDR) prostate brachytherapy is an accepted, effective and safe therapy for localized prostate cancer in
patients with transurethral resection. We analyzed oncologic outcome, side-effects and complications after I-125 brachytherapy
based on 11 years of experience.
Methods and materials. Between June 2000 and December 2005, 56 consecutive patients were treated with clinically localized
prostate cancer. No patients received external beam radiation. All of them underwent LDR prostate brachytherapy. Biochemi-
cal failure was deﬁned according to the “Phoenix consensus”. Patients were stratiﬁed as intermediate risk based on D’Amico
deﬁnition.
Results. The median follow up time for these 56 patients was 100 months; 2 had a clinical relapse and 4 had biochemical relapse.
The 11-year actuarial biochemical control was 92%, (SD ±3%) for overall group. The multivariate Cox regression analyses no
identiﬁed, independent prognostic factors for biochemical failure. The actuarial biochemical control with Gleason score was 93%
and 88% for patients with Gleason score of ≤6 and =7, respectively. The biochemical control was 95%, and 85% for patients with
PSA of ≤10 and >20ng/ml, respectively. A patient reported incontinence after treatment (1,7%). Acute urinary retention was seen
in 2 (3.5%). Gastrointestinal toxicity grade III–IV has been observed in 2 patients (3.5%).
Conclusions. The excellent long-term results and low morbidity presented, as well as the many advantages of prostate brachyther-
apy over other treatments, demonstrates that brachytherapy is an effective treatment for patients with transurethral resection
and clinical organ-conﬁned prostate cancer.
http://dx.doi.org/10.1016/j.rpor.2013.03.704
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Purpose/objective. Study the blood supply of uveal melanoma as a sign of tumoral activity and quantify its presence after
brachytherapy.
Materials and methods. 50 cases treated with brachytherapy were reviewed from July 2005 to June 2010. Mean follow-up was 29
months (13.7–69 months). Duplex Doppler scans (gray scale and Doppler scans) were done at diagnosis and every 6 months after
treatment. Presence of intratumoral vessels, maximum systolic and diastolic velocity and resistance index were evaluated. The
average age was 60 years; 26 ♂ and 24 ♀. Mean basal size and thickness at diagnosis were 12.1mm×5.6mm (SD 3.0–5.6). The
most used plaque was COMS type. Apical dose was 85Gy.
Results. Doppler detected intratumoral vascularization at diagnosis in 21/50 cases, 7 persisted at 6, 12 and 18 months, to 24
months 5/31, 30 months 3/20, 36 months 1/12, 42 months 1/6, 48 months 1/3, 54 months 1/2 and 60 months 0/1. Mean systolic
